Boston Scientific (NYSE:BSX) Stock Sale Reported by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Boston Scientific stock on August 31st. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Boston Scientific Trading Down 0.8%

Boston Scientific stock traded down $0.36 during mid-day trading on Tuesday, hitting $43.74. 14,167,768 shares of the stock were exchanged, compared to its average volume of 18,788,680. The stock has a market capitalization of $63.40 billion, a price-to-earnings ratio of 17.71, a PEG ratio of 1.05 and a beta of 0.57. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm’s fifty day simple moving average is $46.97 and its two-hundred day simple moving average is $52.24.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the firm posted $0.75 EPS. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts forecast that Boston Scientific Corporation will post 3.27 EPS for the current year.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently modified their holdings of the business. QRG Capital Management Inc. boosted its holdings in Boston Scientific by 129.4% in the 2nd quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider’s stock worth $16,031,000 after buying an additional 211,855 shares during the period. Andra AP fonden raised its holdings in Boston Scientific by 13.9% during the 2nd quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider’s stock valued at $8,264,000 after acquiring an additional 23,694 shares during the period. SkyView Investment Advisors LLC purchased a new stake in shares of Boston Scientific during the second quarter worth $107,000. Bullseye Investment Management LLC bought a new position in shares of Boston Scientific in the second quarter worth $41,000. Finally, Rench Wealth Management Inc. boosted its holdings in shares of Boston Scientific by 27.5% in the second quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider’s stock worth $1,193,000 after acquiring an additional 6,033 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, CEO Michael Mahoney acquired 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director David Habiger bought 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. UBS Group cut their target price on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Stifel Nicolaus set a $60.00 price objective on shares of Boston Scientific in a report on Wednesday, July 29th. TD Cowen reissued a “buy” rating on shares of Boston Scientific in a research report on Thursday, September 17th. Finally, Argus restated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Twenty-three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $70.19.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.